All consecutive patients responding to the inclusion criteria were included. Inclusion criteria were: age ≥18 years; performance status by Eastern Cooperative Oncology Group (ECOG PS) 0–1; well-differentiated NETs (GEP) and typical or atypical carcinoids (thoracic), according to WHO’s 2019 classification [27 ]; grading 1-2-3, according to WHO’s 2019 classification; primary site (pancreas, gastro-intestinal tract, lung); locally advanced (III) or metastatic (IV) stage; and availability of tissue for MGMT-promoter methylation status analysis (formalin-fixed, paraffin-embedded tissue) from biopsy or surgical resection of tumor (primary or metastasis). Patients had to be considered by clinician’s choice as candidates for TEM-based treatments with either TEM alone (180–200 mg/mq day 1–5 every 4 weeks) or CAPTEM (capecitabine 1500 mg/sqm day 1–14 in two daily doses and TEM 180–200 mg/sqm day 10–14, every 4 weeks) as indicated by clinical guidelines [5 (link),6 (link),7 (link),8 (link)].
Free full text: Click here
